Study Finds Elevated Liver Enzymes in Healthy Adults Using Cannabidiol
CBD is a common chemical compound found in the cannabis plant, specifically in both hemp and marijuana. Unlike tetrahydrocannabinol (THC), another common cannabinoid, CBD does not produce a psychoactive effect, also called the 'high.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Exhale Wellness Recognized as the #1 Delta 9 THC Gummies by Onpattison
Exhale Wellness earns top spot for best Delta 9 gummies in 2025, recognized for quality, transparency, and customer satisfaction by Onpattison. Charlotte, NC, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Onpattison has named Exhale Wellness the #1 Delta 9 gummy brand in its 2025 rankings, citing the company's emphasis on clean formulations, product transparency, and third-party testing. The annual list, compiled by the publication's wellness editorial team, highlighted 5 standout hemp-derived THC products that met high standards for safety, effectiveness, and consumer trust. Exhale Wellness's plant-based approach and commitment to rigorous quality control played a key role in securing the top spot for the brand. What Are Delta 9 Gummies? Delta 9 gummies are edible products containing Delta 9 tetrahydrocannabinol (THC), the primary psychoactive compound in cannabis. When sourced from federally legal hemp and formulated within compliant THC limits (less than 0.3% Delta 9 THC), these gummies offer a controlled, predictable way to consume THC. In its 2025 ranking, Onpattison recognized brands that deliver not only efficacy but also transparency and consumer safety in their Delta 9 offerings, criteria that Exhale Wellness met with distinction. Delta 9 THC Gummies: The Flagship Behind the #1 RankingAt the center of Onpattison's ranking is Exhale Wellness's Delta-9 Bottle Caps, the company's flagship gummy product. Editors cited the product's balanced potency, full-spectrum formulation, and transparency in testing as key reasons for awarding Exhale the top spot. Each bottle contains 450 mg of hemp-derived Delta 9 THC, formulated from full-spectrum hemp extract to preserve the natural cannabinoid and terpene profile. This approach contributes to what users often describe as a more rounded, longer-lasting experience compared to isolates. Bottle Caps were also recognized for their clean formulation, including vegan ingredients and naturally flavored profiles such as Cherry Cola, Lemon-Lime, and Orange. Exhale's use of U.S.-grown hemp and third-party lab testing ensures that each batch meets federal compliance standards outlined in the 2018 Farm Bill. In this context, Exhale's published Certificates of Analysis (COAs), available to consumers, were noted as a strong indicator of transparency and consumer trust. Additional Features That Contributed to the Best Ranking In naming Exhale Wellness the #1 Delta 9 thc gummy brand of 2025, Onpattison highlighted several distinguishing factors beyond formulation alone. One was consistency in potency, with each gummy delivering a reliable 15 mg of hemp-derived Delta 9 THC, an important element for responsible dosing and user experience. The product's clean, vegan formulation was also a factor in the ranking. Made with plant-based pectin, natural flavors, and free from artificial additives, Bottle Caps reflects growing consumer demand for health-conscious, non-GMO edibles. While the Bottle Caps line is relatively new, Onpattison noted Exhale's overall brand reputation for quality and transparency. Across its product offerings, Exhale has earned strong consumer reviews for consistency, ease of use, and customer service, qualities that helped set the brand apart in a competitive evaluation process. Why Exhale Wellness Was Chosen as Delta 9 Gummies? Exhale Wellness earned the top spot in Onpattison's 2025 Delta 9 thc gummy rankings due to its commitment to product integrity, transparency, and user trust. The evaluation highlighted several standout factors that contributed to the brand's placement: Transparent Sourcing and Lab TestingEach batch of Exhale's Delta 9 gummies is verified through third-party lab testing, with publicly available Certificates of Analysis (COAs) confirming cannabinoid content, potency, and product safety. This level of transparency was a key differentiator in the ranking process. Clean, Plant-Based FormulationsThe editorial team emphasized Exhale's use of organic, non-GMO ingredients and vegan-friendly formulations made without artificial additives. The use of pectin over gelatin reflects a thoughtful approach to ingredient sourcing. Established Brand ReputationWhile Bottle Caps is one of the newer products in Exhale's portfolio, the brand's track record of quality and responsiveness was cited as a contributing factor. Consistent consumer satisfaction across Exhale's broader product line reinforced its credibility. Balanced Potency and Full-Spectrum EffectThe magazine also acknowledged the company's use of full-spectrum hemp extract, which preserves a range of cannabinoids and terpenes for a more comprehensive user experience. This format, paired with clearly labeled dosing, supports a wide range of consumer preferences. Editorial Criteria That Set Exhale Wellness Apart In evaluating the best Delta 9 THC gummies for its 2025 ranking, Onpattison applied a broad set of criteria reflecting the current standards for product quality and consumer trust. Exhale Wellness met or exceeded expectations across the following key areas: Sourcing and Agricultural Standards Exhale uses hemp grown in the United States under regulated agricultural practices, minimizing exposure to pesticides, heavy metals, or synthetic additives. Domestic sourcing was a baseline requirement in the magazine's review process. Potency and Dose TransparencyEach gummy contains a clearly labeled 15 mg of Delta 9 THC. The publication highlighted brands that offer reliable, consistent dosing, a crucial element for consumers managing intake responsibly. Clean Ingredient Profile Formulations were evaluated for ingredient transparency. Exhale's plant-based, vegan gummies, made without artificial colorants or high-fructose corn syrup, were noted for addressing evolving consumer preferences. Third-Party Lab Testing and COA Access Brands without published lab results were excluded from consideration. Exhale's publicly accessible Certificates of Analysis (COAs) confirmed potency, cannabinoid breakdown, and absence of contaminants. Flavor and Product Consistency Taste and texture factored into the overall experience. Exhale's use of natural flavoring and consistent formulation across batches contributed positively to its assessment. Responsiveness Exhale's reputation for customer support, shipping reliability, and product consistency helped distinguish it in a crowded market. Editorial staff considered both consumer sentiment and company transparency during the review. Legal Compliance All selected brands were required to meet the 2018 Farm Bill threshold of 0.3% Delta 9 THC by dry weight. Exhale's compliance was verified through both internal documentation and third-party reports. Exhale Wellness's Delta 9 Gummies Availability Exhale Wellness's Delta 9 gummies, including the award-winning Bottle Caps line, are available for purchase through the company's official website. Each product listing includes detailed lab reports (COAs), ingredient information, and dosage specifications to support consumer transparency. All Exhale Wellness Delta 9 THC products comply with the 2018 Farm Bill, containing no more than 0.3% THC by dry weight. Products are available for shipment to states where hemp-derived Delta 9 THC is permitted, and all customers must be 21 years or older to purchase. Shipping practices adhere to federal and state-level compliance requirements. FAQs about Delta THC Gummies What is Delta 9 THC? Delta 9 tetrahydrocannabinol (THC) is the primary psychoactive compound found in cannabis. It interacts with the body's endocannabinoid system and is known for producing effects such as euphoria and relaxation. When derived from hemp and used within legal limits, it can be formulated into federally compliant wellness products. Are Exhale Wellness's Delta 9 Gummies Legal? Yes. Exhale Wellness's Delta 9 gummies are made from hemp-derived THC and contain no more than 0.3% Delta 9 THC by dry weight, in accordance with the 2018 Farm Bill. Federal legality does not guarantee state-level approval, so consumers are advised to check local laws before purchasing. What makes Exhale Wellness different from other Delta 9 gummy brands? Exhale Wellness was recognized by Onpattison for its product consistency, lab-tested transparency, and clean ingredient profile. The brand uses non-GMO, vegan-friendly formulations and publishes third-party Certificates of Analysis for every batch. How strong are the best Delta 9 Gummies from Exhale Wellness? Each gummy contains 15 mg of hemp-derived Delta 9 THC. This dosage format offers a balanced and consistent experience and is intended to support responsible use among both new and experienced consumers. Do Exhale Wellness's gummies ship nationwide? Exhale Wellness ships to U.S. states where hemp-derived Delta 9 THC products are legally permitted. While the products are federally legal, shipping availability is subject to state-specific regulations. How long do the effects last? The effects of hemp-derived Delta 9 gummies typically last between 6 and 9 hours, depending on individual factors such as body chemistry, metabolism, and tolerance. Onset time may be delayed due to digestion. How should Delta 9 THC be dosed? Dosing recommendations vary by user. For those new to Delta 9 THC, a lower dose (such as 2.5 to 5 mg) is generally suggested to gauge individual response. Gradual adjustment over time can help maintain a safe and comfortable experience. Conclusion Exhale Wellness's selection as the top Delta 9 gummy brand in Onpattison's 2025 rankings reflects the company's emphasis on ingredient transparency, consistent dosing, and third-party lab testing. The recognition highlights Exhale's approach to federally compliant hemp products at a time when consumer standards for quality and accountability in the wellness space are rising. For more information, visit CONTACT: Company Name: Exhale Wellness Phone Number: (323) 448-3810 Email: support@ Official Address: Charlotte, NC 28273, United StatesSign in to access your portfolio
Yahoo
3 days ago
- Yahoo
Alabama CBD Customers: SUNMED Stores Are Open and Thriving
Sunmed™ | Your CBD Store® welcomes Alabama CBD customers! BIRMINGHAM, Ala., Aug. 1, 2025 /PRNewswire/ -- Your Alabama Sunmed™ | Your CBD Store® locations are open for business and carrying a full inventory of compliant, clinically proven and high-quality premium hemp and CBD full and broad-spectrum products. In appreciation of its customers' continued support, participating SUNMED stores across Alabama are offering FREE Wellness Gummy ($60 value). Promo Code: VIPAL25* Sunmed always strives to offer consumers wellness and therapeutic products that meet the highest standards with respect to quality, consumer safety and satisfaction. Recently enacted regulatory changes in Alabama had little or no impact with respect to Sunmed's CBD and hemp products. Sunmed welcomes reasonable regulations that guarantee consumer's access to Sunmed's wide variety of wellness goods and provide Sunmed small business store owners with the opportunity to continue to serve the community. Across Alabama please visit any of Sunmed | Your CBD Store Locations – Sunmed CBD. Offer valid at participating stores while products last. Additional restrictions apply. Void where prohibited, this offer cannot be combined with other offers. Limit 1 per household. Contact Patrick ShatzerSunmed l Your CBD Storecustomersupport@ About Sunmed™ | Your CBD Store® Sunmed | Your CBD Store, an affiliate of Sunflora, Inc., is the largest hemp retailer in the United States and the exclusive home of award-winning, hemp-derived Sunmed products. With 260+ nationwide locations across 39 states, the brand offers a premium in-store customer experience with access to 150+ nonpharmaceutical wellness formulas, including clinically proven sleep gummies, pain relief topicals, USDA-organic oil tinctures, and CBD for pets. Through in-store education, community involvement, and groundbreaking clinical research, Sunmed strives to empower modern wellness and enhance people's lives with natural science-backed products. Learn more at View original content to download multimedia: SOURCE Sunmed Sign in to access your portfolio
Associated Press
3 days ago
- Associated Press
Artelo Biosciences Receives Favorable UK MHRA Guidance for a Phase 1 Trial of ART12.11, the Company's Proprietary CBD:TMP Cocrystal Being Developed for the Treatment of Anxiety and Depression
SOLANA BEACH, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. ('Artelo' or the 'Company') (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced that it has received written scientific advice from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) on the nonclinical development and first-in-human (FIH) clinical study plans for ART12.11, a novel cocrystal of Cannabidiol (CBD) and Tetramethylpyrazine (TMP). The MHRA agreed that reliance on the substantial body of historic nonclinical and clinical evidence for CBD, alongside legacy data for TMP, provides a scientifically justified basis for a streamlined clinical trial application (CTA)-enabling nonclinical development plan of the cocrystal combination to support the proposed FIH study, with clear guidance for achieving the agreed-upon FIH study design for ART12.11. The agency also affirmed that the proposed first-in-human (FIH) study design—a single-dose, multi-formulation crossover study—was methodologically sound for characterizing ART12.11's pharmacokinetic profile. Importantly, the MHRA offered constructive and specific guidance for completing the data package supporting the agreed-upon Phase 1 trial. Additionally, the agency proposed that ART12.11 may be a candidate for the Innovative Licensing and Access Pathway (ILAP). ILAP offers a unique opportunity to accelerate the development and patient access of promising new therapies through early and sustained collaboration with the MHRA, National Health Service, and health technology assessment bodies. Given ART12.11's novel mechanism and potential to address unmet needs in anxiety and depression, Artelo believes the program aligns well with ILAP's criteria and will evaluate a formal application to enter the pathway in the coming months. 'It's gratifying to receive this positive feedback and actionable recommendations from the MHRA, which provides a clear path forward as we prepare to initiate clinical studies with ART12.11,' said Dr. Andrew Yates, Chief Scientific Officer at Artelo. 'The recommendation to explore ILAP reinforces the proposition of ART12.11 as a novel drug with the potential to transform the treatment landscape for anxiety and depression.' Multiple nonclinical studies with ART12.11 have shown its promising profile compared to an antidepressant or CBD alone. The Company recently announced positive preclinical results in a depression model comparing ART12.11 with sertraline (Zoloft), a selective serotonin reuptake inhibitor (SSRI), where Artelo's patented CBD:TMP cocrystal demonstrated efficacy on par with sertraline and showed superior cognitive restoration compared to the leading SSRI. Additionally, in a rodent model of stress-induced anxiety and depression, where ART12.11 was compared to CBD dosed at 300% the amount of CBD contained in the oral tablet of ART12.11, the CBD:TMP cocrystal demonstrated efficacy where CBD alone did not. 'The clear regulatory assurance from the regulatory authority in the UK is expected to reduce expenses for our ART12.11 program,' added Gregory Gorgas, President & CEO at Artelo. 'We are especially pleased with the potential for an accelerated development strategy which could greatly accelerate our progress with ART12.11 and could provide for a longer period of market exclusivity as our patents are valid in 20 countries through the end of 2038. Over the next few months we look forward to finalizing our preparations to enter the clinic with ART12.11 early next year.' About ART12.11 ART12.11 is Artelo's wholly owned, proprietary cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP). Isolated as a single crystalline form, ART12.11 has exhibited better pharmacokinetics and improved efficacy compared to other forms of CBD in nonclinical studies. Greatly enhanced pharmaceutical properties, including physicochemical, pharmacokinetic, and pharmacodynamic advantages have been observed with ART12.11. Artelo believes a more consistent and improved bioavailability profile in a solid dosage form may ultimately lead to increased safety and efficacy in humans, thus making ART12.11 a preferred CBD pharmaceutical composition. The U.S. issued composition of matter patent for ART12.11 is enforceable until December 10, 2038, and has now been granted or validated in 19 additional countries. About Artelo Biosciences Artelo Biosciences, Inc. is a clinical stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the Company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at and Twitter: @ArteloBio. Forward Looking Statements Investor Relations Contact: Crescendo Communications, LLC Tel: 212-671-1020 Email: [email protected]
